206761-91-3

Usage

Uses

Used in Pharmaceutical Industry:
2,4,6-Trifluorophenyl isothiocyanate is used as a key intermediate in the synthesis of pharmaceuticals for its ability to introduce the isothiocyanate functional group into drug molecules, enhancing their therapeutic properties and effectiveness.
Used in Agrochemical Industry:
In the agrochemical sector, 2,4,6-Trifluorophenyl isothiocyanate is employed as a reagent in the development of agrochemicals, where it contributes to the creation of compounds with improved pesticidal or herbicidal activities.
Used in Specialty Chemicals and Materials Synthesis:
2,4,6-Trifluorophenyl isothiocyanate is used as a building block for the synthesis of specialty chemicals and materials, leveraging its strong and stable nature to create compounds with unique properties for various applications.
Used in Organic Synthesis:
As a versatile reagent in organic synthesis, 2,4,6-Trifluorophenyl isothiocyanate is used for the modification of different molecules, allowing for the development of new compounds with specific functional groups and improved characteristics for research and industrial purposes.

InChI:InChI=1/C7H2F3NS/c8-4-1-5(9)7(11-3-12)6(10)2-4/h1-2H

Upstream product

• 363-81-5 2,4,6-trifluoroaniline 
• 16420-13-6 N,N-Dimethylthiocarbamoyl chloride 

Downstream Products

• 1242015-79-7 4-(2,6-difluoro-4-methoxyphenyl)-1,3-dimethyl-N-(2,4,6-trifluorophenyl)-1H-pyrazol-5 amine 

Relevant academic research and scientific papers

Pyrazolopyrimidines: Potent Inhibitors Targeting the Capsid of Rhino- and Enteroviruses

There are currently no drugs available for the treatment of enterovirus (EV)-induced acute and chronic diseases such as the common cold, meningitis, encephalitis, pneumonia, and myocarditis with or without consecutive dilated cardiomyopathy. Here, we report the discovery and characterization of pyrazolopyrimidines, a well-tolerated and potent class of novel EV inhibitors. The compounds inhibit the replication of a broad spectrum of EV in vitro with IC50 values between 0.04 and 0.64 μM for viruses resistant to pleconaril, a known capsid-binding inhibitor, without affecting cytochrome P450 enzyme activity. Using virological and genetics methods, the viral capsid was identified as the target of the most promising, orally bioavailable compound 3-(4-trifluoromethylphenyl)amino-6-phenylpyrazolo[3,4-d]pyrimidine-4-amine (OBR-5-340). Its prophylactic as well as therapeutic application was proved for coxsackievirus B3-induced chronic myocarditis in mice. The favorable pharmacokinetic, toxicological, and pharmacodynamics profile in mice renders OBR-5-340 a highly promising drug candidate, and the regulatory nonclinical program is ongoing. Curing the common cold! A cluster of pyrazolopyrimidines with potent broad-spectrum activity against enteroviruses was discovered. Extensive structure-property relationship analyses led to the identification of 3-(4-trifluoromethyl-phenyl)amino-6-phenylpyrazolo[3,4-d]pyrimidine-4-amine, shown to be a blocker of the viral capsid protein, as a lead compound for drug development with favorable physicochemical, pharmacokinetic, and toxicological properties.